Early-Phase Data Support Novel Contrast Agent

ASE 2026 data support further development of MVT-100 in pivotal trials.

To evaluate the safety and efficacy of the novel perflutren-based ultrasound-enhancing agent MVT-100 compared to Definity in healthy volunteers.

Study Design: A prospective interventional phase 1/2 study involving healthy volunteers who underwent echocardiography and received ascending dilute bolus doses of MVT-100 or Definity.
Monitoring: Participants were monitored for vital signs, ECGs, and laboratory tests before and after contrast administration.
Evaluation: Three expert echocardiographers evaluated images for left ventricular opacification and acoustic shadowing, blinded to the administered agent.

No serious adverse events reported for either MVT-100 or Definity.
No clinically significant changes in vital signs, ECG, or laboratory parameters post-administration.
MVT-100 produced higher left ventricular opacification scores than Definity across all dose levels.
Overall shadowing rates were approximately 3% with MVT-100 compared to 8% with Definity.
Statistically significant reductions in acoustic shadowing observed across most left ventricular segments.